{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:24:39Z","timestamp":1792448679667,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274319"],"award-info":[{"award-number":["82274319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109474","type":"journal-article","created":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T11:29:16Z","timestamp":1668943756000},"page":"109474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"PB","title":["Targeted inhibition of FcRn reduces NET formation to ameliorate experimental ulcerative colitis by accelerating ANCA clearance"],"prefix":"10.1016","volume":"113","author":[{"given":"Chengming","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-6065","authenticated-orcid":false,"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.109474_b0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7861\/clinmed.2021-0080","article-title":"Ulcerative colitis: an update","volume":"21","author":"Segal","year":"2021","journal-title":"Clin. Med. (Lond)"},{"issue":"4","key":"10.1016\/j.intimp.2022.109474_b0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.gtc.2020.07.001","article-title":"Ulcerative Colitis: making the diagnosis","volume":"49","author":"Kaenkumchorn","year":"2020","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.intimp.2022.109474_b0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.intimp.2022.109474_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12950-020-00246-4","article-title":"Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies","volume":"17","author":"Kaur","year":"2020","journal-title":"J. Inflamm. (Lond.)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109474_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109474_b0030","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cei\/uxac005","article-title":"Expression levels of cellular inhibitor of apoptosis proteins and colitogenic cytokines are inversely correlated with the activation of interferon regulatory factor 4","volume":"207","author":"Masaki","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2022.109474_b0035","article-title":"Ulcerative colitis: Gut microbiota, immunopathogenesis and application of natural products in animal models","volume":"258","author":"Nascimento","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.109474_b0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.imlet.2022.07.006","article-title":"Annickia polycarpa extract attenuates inflammation, neutrophil recruitment, and colon damage during colitis","volume":"248","author":"Lartey","year":"2022","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.intimp.2022.109474_b0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.109474_b0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fimmu.2017.00081","article-title":"Neutrophil extracellular traps and its implications in inflammation: an overview","volume":"8","author":"Delgado-Rizo","year":"2017","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109474_b0055","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.4049\/jimmunol.1201719","article-title":"Neutrophil extracellular traps: double-edged swords of innate immunity","volume":"189","author":"Kaplan","year":"2012","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109474_b0060","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2022.109474_b0065","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ecco-jcc\/jjy215","article-title":"Neutrophil extracellular traps sustain inflammatory signals in ulcerative colitis","volume":"13","author":"Dinallo","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.intimp.2022.109474_b0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrneph.2016.71","article-title":"The role of neutrophils and NETosis in autoimmune and renal diseases","volume":"12","author":"Gupta","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.intimp.2022.109474_b0075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2016.00302","article-title":"New insights into neutrophil extracellular Traps: mechanisms of formation and role in inflammation","volume":"7","author":"Yang","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109474_b0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13223-020-00433-1","article-title":"Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis","volume":"16","author":"Pang","year":"2020","journal-title":"Allergy Asthma. Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109474_b0085","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.autrev.2016.07.016","article-title":"The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA)","volume":"15","author":"Weiner","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2022.109474_b0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12016-012-8349-4","article-title":"Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease","volume":"45","author":"Arias-Loste","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109474_b0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","article-title":"Pathogenesis and therapeutic interventions for ANCA-associated vasculitis","volume":"15","author":"Nakazawa","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109474_b0100","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and Albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109474_b0105","first-page":"682","article-title":"Unraveling the Interaction between FcRn and Albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.intimp.2022.109474_b0110","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1002\/cam4.3067","article-title":"The neonatal Fc receptor in cancer FcRn in cancer","volume":"9","author":"Cadena Castaneda","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2022.109474_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107574","article-title":"The biodistribution of therapeutic proteins: mechanism, implications for pharmacokinetics, and methods of evaluation","volume":"212","author":"Conner","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.109474_b0120","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/s41467-019-10865-y","article-title":"Human cytomegalovirus evades antibody-mediated immunity through endoplasmic reticulum-associated degradation of the FcRn receptor","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2022.109474_b0125","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.intimp.2022.109474_b0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2022.109474_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.109474_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2022.109474_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10051004","article-title":"Emerging therapies in immune thrombocytopenia","volume":"10","author":"Audia","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109474_b0150","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.109474_b0155","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"issue":"2","key":"10.1016\/j.intimp.2022.109474_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020559","article-title":"Neutrophil extracellular traps and their implications in cardiovascular and inflammatory disease","volume":"22","author":"Klopf","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2022.109474_b0165","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.devcel.2018.01.019","article-title":"Neutrophil extracellular traps: the biology of chromatin externalization","volume":"44","author":"Sollberger","year":"2018","journal-title":"Dev. Cell"},{"issue":"3","key":"10.1016\/j.intimp.2022.109474_b0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109474_b0175","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2022.109474_b0180","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.gtc.2020.08.002","article-title":"Biologic therapy for ulcerative colitis","volume":"49","author":"Bhattacharya","year":"2020","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"10","key":"10.1016\/j.intimp.2022.109474_b0185","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922009596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:47:36Z","timestamp":1761587256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922009596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":37,"alternative-id":["S1567576922009596"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109474","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted inhibition of FcRn reduces NET formation to ameliorate experimental ulcerative colitis by accelerating ANCA clearance","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109474"}}